/

Wenyan Chen1, Lu Lv1, Na Chen1

  • 1Department of Respiratory and Critical Care Medicine, Huzhou Central Hospital, Affiliated Huzhou Hospital, Zhejiang University School of Medicine, 313000, Zhejiang, No. 1558, Third Ring North Road, Huzhou, China.

概括

介酶体 stromal 细胞 (MSCs) 由于其再生和免疫调节性质,显示出治疗前景. 然而,它们的临床使用受到潜在的免疫排斥的限制,需要进一步的安全研究.